Mirati Therapeutics, Inc.

Good afternoon, and welcome to the Mirati Therapeutics first quarter 2023 earnings call. My name is Justin, and I will be the operator for today's call. All lines have been placed on mute to prevent any background noise. After the conclusion of the speaker's prepared remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by number one on your telephone keypad. If you would like to withdraw your question, press star 2. It is my pleasure to introduce Ryan Acy, Vice President of Corporate Affairs at Mirati. Ryan, you may begin the call.

Thank you, Justin, and welcome everyone to this afternoon's call. Joining me on the call today are David Meek, our Chief Executive Officer, Dr. Chuck Baum, our President, Founder, and Head of Research and Development, Dr. Alan Sandler, our Chief Medical Officer, Dr. Jamie Christensen, our Chief Scientific Officer, Ben Hickey, our Chief Commercial Officer, and Laurie Stelzer, our Chief Financial Officer. Before we begin, I'd like to inform you that certain statements we make during this call will be forward-looking because such statements deal with future events and are subject to many risks and uncertainties. Actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K and our quarterly reports on Form 10-Q that are filed with the U.S. Securities and Exchange Commission. This afternoon, we released financial results for the quarter ended March 31st, 2023, and recent corporate updates. This press release is available on the investor section of our website at merati.com. With that, David, I'll turn the call over to you.

Thank you, Ryan, and thank you all for joining us on the call today. On this afternoon's call, I will provide initial remarks before turning the call over to Ben, Alan, Jamie, and Lori to provide updates. I'll then provide some closing remarks before we open the line for questions. I'm pleased to report that 2023 is off to a great start. I'll touch on the key highlights from the first quarter, starting with the Corsati launch performance. We are delighted to see the rapid acceptance of Corsati, which was driven by Corsati's differentiated profile and our highly experienced lung cancer commercial team. We also began enrolling patients in a clinical study for MRTX1133, our highly selective and potent oral KRAS G12D inhibitor, Our MTA-cooperative PRMT5 inhibitor and our KRAS-enabling SOS1 inhibitor continue to move in a positive direction. In addition, we expect to communicate the top-line outcome of the Phase III SAFIRE study this quarter. A positive result would be a transformational milestone for Merati. Furthermore, in this quarter, we continue to employ a data-driven approach to capital deployment and remain fiscally vigilant and continue to explore XUS partnerships as a source of capital and risk sharing, and as a means of further strengthening our balance sheet. We continue to be optimistic and very excited about the future of Merati. The full potential of Krizati, combined with our innovative pipeline, represents an opportunity to help hundreds of thousands of people in need and create substantial value in the process. I'll now turn the call over to Ben, who will provide an update on our Krizati launch. Ben?